


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

11/2/00
TOWNSEND and TOWNSEND and CREW LLP

By: 



GA/1642/H

PATENT

Attorney Docket No.: 15280P-001000US
Client Reference No.: E-160-98/0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Peter L. Collins, et al.

Application No.: 09/291,894

Filed: April 13, 1999

For: PRODUCTION OF ATTENUATED
CHIMERIC RESPIRATORY
SYNCYTIAL VIRUS VACCINES
FROM CLONED NUCLEOTIDE
SEQUENCES

Examiner: B. Brumback

Art Unit: 1642

AMENDMENT AND RESPONSE TO
RESTRICTION REQUIREMENT

RECEIVED
NOV 20 2000
TECH CENTER 1600/2900

#9/A
KD
11-22-00

Assistant Commissioner for Patents
Washington, D.C. 20231

Examiner Brumback:

In response to the Restriction Requirement dated June 7, 2000, please amend the claims of the application as follows:

Please cancel claim 36-45, without prejudice, to withdraw from consideration claims directed to methods for stimulating an immune response.

Please amend claims 1-3, 52-54, 64 and 65, without prejudice, as follows.

- AI
- 1 1. (Amended) An isolated infectious chimeric respiratory syncytial virus
2 (RSV) comprising a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a
3 large polymerase protein (L), a RNA polymerase elongation factor, and a partial or complete
4 RSV genome or antigenome of one human RSV strain or subgroup virus combined with a
5 heterologous gene or gene segment of a different human RSV strain or subgroup virus to form
6 a chimeric RSV genome or antigenome.
- 